

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:

G16E

100%

pos=10,161

•

E35D

100%

pos=19,408

•

M36V

100%

pos=10,403

•

R41K

100%

pos=40,403

•

R57K

100%

pos=42,112

•

L63C

100%

pos=19,421

•

H69K

100%

pos=11,122

•

L89M

100%

pos=18,117

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:None

NNRTI Mutations:

K103N

100%

pos=18,108

•

V106M

100%

pos=18,111

•

P225H

100%

pos=11,109

RT Other Mutations:

I5V

100%

pos=22,175

•

V35T

100%

pos=18,187

•

V60I

100%

pos=18,200

•

K122E

100%

pos=18,197

•

D123N

100%

pos=18,194

•

I135T

100%

pos=17,197

•

K173A

100%

pos=10,192

•

Q174K

100%

pos=10,196

•

D177E

100%

pos=19,105

•

I178M

100%

pos=19,108

•

V179I

100%

pos=19,106

•

T200A

100%

pos=12,142

•

Q207E

100%

pos=10,132

•

V245E

100%

pos=4,174

•

T286A

100%

pos=6,708

•

I293V

100%

pos=6,187

•

P294T

100%

pos=6,187

•

E312D

100%

pos=6,105

•

V317A

100%

pos=6,102

•

G335D

100%

pos=46

•

M357K

100%

pos=67

•

G359S

100%

pos=66

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	High-Level Resistance
zidovudine (AZT)	Susceptible	efavirenz (EFV)	High-Level Resistance
emtricitabine (FTC)	Susceptible	etravirine (ETR)	Susceptible
lamivudine (3TC)	Susceptible	nevirapine (NVP)	High-Level Resistance
tenofovir (TDF)	Susceptible	rilpivirine (RPV)	Susceptible

RT comments

NNRTI

- K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
- V106M is a non-polymorphic mutation that confers high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it reduces DOR susceptibility about 3-fold.
- P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.

Other

- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR ⚖	EFV ⚖	ETR ⚖	NVP ⚖	RPV ⚖
K103N + P225H	10	0	0	0	0
V106M	30	60	0	60	0
P225H	20	45	0	45	0
K103N	0	60	0	60	0
Total	60	165	0	165	0